NO883974L - Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.

Info

Publication number
NO883974L
NO883974L NO88883974A NO883974A NO883974L NO 883974 L NO883974 L NO 883974L NO 88883974 A NO88883974 A NO 88883974A NO 883974 A NO883974 A NO 883974A NO 883974 L NO883974 L NO 883974L
Authority
NO
Norway
Prior art keywords
hydroxypyranon
derivatives
procedure
preparation
therapeutic active
Prior art date
Application number
NO88883974A
Other languages
English (en)
Norwegian (no)
Other versions
NO883974D0 (no
Inventor
Alexander Wilhelm Chucholowski
Bruce David Roth
Mark Wallace Creswell
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO883974D0 publication Critical patent/NO883974D0/no
Publication of NO883974L publication Critical patent/NO883974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO88883974A 1987-09-08 1988-09-07 Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater. NO883974L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9419887A 1987-09-08 1987-09-08
US07/226,190 US4906624A (en) 1987-09-08 1988-08-02 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Publications (2)

Publication Number Publication Date
NO883974D0 NO883974D0 (no) 1988-09-07
NO883974L true NO883974L (no) 1989-03-09

Family

ID=26788605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO88883974A NO883974L (no) 1987-09-08 1988-09-07 Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.

Country Status (10)

Country Link
US (1) US4906624A (fr)
EP (1) EP0306929A3 (fr)
JP (1) JPH01121266A (fr)
KR (1) KR890005089A (fr)
AU (1) AU620559B2 (fr)
DK (1) DK497488A (fr)
FI (1) FI884080A7 (fr)
NO (1) NO883974L (fr)
NZ (1) NZ226063A (fr)
PT (1) PT88442B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
PT87929B (pt) * 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3925636A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine
US5183897A (en) * 1989-08-03 1993-02-02 Bayer Aktiengesellschaft Certain intermediate imino-substituted pyridines
DE3929507A1 (de) * 1989-09-06 1991-03-07 Bayer Ag Substituierte amino-pyridine
NZ237097A (en) * 1990-02-26 1993-12-23 Squibb & Sons Inc Pyridine derivatives substituted in the 3-position by a phosphinic moiety.
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5288928A (en) * 1990-12-21 1994-02-22 Ciba-Geigy Corporation Asymmetrical hydrogenation
EG21314A (en) 1992-07-16 2000-10-31 Driutt Rodney Malcolm Tamper evident closure
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
DE4244029A1 (de) * 1992-12-24 1994-06-30 Bayer Ag Neue substituierte Pyridine
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6812345B2 (en) 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
DE10135013A1 (de) * 2001-07-18 2003-01-30 Bayer Ag Herstellung von Pyridylverbindungen
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
CA2510319A1 (fr) * 2002-12-20 2004-07-15 Thomas J. Smith Compactage haute pression pour formulations pharmaceutiques
EP1510208A1 (fr) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
NZ563759A (en) 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
CA2659082A1 (fr) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Marqueurs associes a des evenements arterio-vasculaires et procedes d'utilisation de ces marqueurs
WO2008026702A1 (fr) 2006-08-30 2008-03-06 Kyushu University, National University Corporation Composition pharmaceutique contenant une nanoparticule de statine encapsulée
TW200849035A (en) 2007-04-18 2008-12-16 Tethys Bioscience Inc Diabetes-related biomarkers and methods of use thereof
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
SG184353A1 (en) 2010-03-31 2012-11-29 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
JP2013523349A (ja) 2010-04-08 2013-06-17 ザ・ホスピタル・フォー・シック・チルドレン 外傷性損傷に対する遠隔虚血コンディショニングの使用
WO2014022195A1 (fr) 2012-08-01 2014-02-06 Tavakoli Zahra Compositions congelées à écoulement libre comprenant un agent thérapeutique
CN110575445B (zh) 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
JP2026521511A (ja) * 2023-06-12 2026-06-30 ザ ジェネラル ホスピタル コーポレイション スタチン誘導体およびそれを用いる方法
EP4553080A1 (fr) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Dérivés de nucléosides utilisés en tant qu'agents antiviraux contre les coronavirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
EP0080847A3 (fr) * 1981-11-27 1984-05-02 Eli Lilly And Company Synthèse de dioxannes analgésiques
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
HU198711B (en) * 1984-06-22 1989-11-28 Sandoz Ag Process for producing mevalolacton, derivatives and pyrazol analogues and pharmaceutical composition containing them
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
PT87929B (pt) * 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte

Also Published As

Publication number Publication date
PT88442B (pt) 1992-11-30
AU2141288A (en) 1989-03-09
NO883974D0 (no) 1988-09-07
US4906624A (en) 1990-03-06
NZ226063A (en) 1991-09-25
EP0306929A3 (fr) 1990-02-07
DK497488A (da) 1989-03-09
PT88442A (pt) 1989-07-31
JPH01121266A (ja) 1989-05-12
AU620559B2 (en) 1992-02-20
FI884080A0 (fi) 1988-09-05
KR890005089A (ko) 1989-05-11
FI884080A7 (fi) 1989-03-09
EP0306929A2 (fr) 1989-03-15
DK497488D0 (da) 1988-09-07

Similar Documents

Publication Publication Date Title
NO883974D0 (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO871266L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO894630D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO870526D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO884231D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazopyridin-derivater.
NO874032D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO883485D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO875488L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO880667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
NO881762D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzazepinderivater.
NO891723D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO884175L (no) Fremgangsmaate for fremstilling av terapeutiske aktive heterocykliske derivater.
NO895220L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzenderivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO881884D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO883959D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.
NO882282L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO890724L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.